Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.
Read More
3 minute read

Revolution Medicines Announces Publications On The Discovery And Preclinical Profile Of Representative Of A New Class Of RAS(ON) Multi-Selective Inhibitors Designed To Block Full Spectrum Of Oncogenic RAS(ON) Proteins

By Benzinga Newsdesk
April 8, 11:38 AM
Two original papers in Nature highlight the discovery and translational implications of RMC-7977, a RAS(ON) multi-selective tri-complex inhibitor that exhibits unprecedented anti-tumor activity in preclinical models of

RVMD

Read More
2 minute read

Bristol Myers Squibb Announces KRAZATI In Combination With Cetuximab Demonstrates Clinically Meaningful Activity As A Targeted Treatment Option For Patients With Previously Treated KRAS G12C-Mutated Locally Advanced Or Metastatic Colorectal Cancer

By Benzinga Newsdesk
April 8, 11:31 AM
Late-breaking data to be featured in an oral presentation at the American Association for Cancer Research (AACR) annual meeting on Monday, April 8 and highlighted as part of the official meeting press programBristol

BMY

Read More
2 minute read

Bristol Myers’ $14B Bet On Schizophrenia – Drug Cuts Symptoms Without Common Side Effect Of Weight Gain Associated With Other Antipsychotics

By Vandana Singh
April 8, 10:31 AM
Interim data from Bristol Myers Squibb's Phase 3 EMERGENT program on KarXT's safety, tolerability, and metabolic outcomes in adults with schizophrenia. Find out how KarXT demonstrated favorable impacts on weight and long-term metabolic profile over 52 weeks of treatment.

BMY

Read More
2 minute read

Supernus Pharmaceuticals Faces Second FDA Rejection For Investigational Device For Parkinson’s Disease

By Vandana Singh
April 8, 10:11 AM
Supernus Pharmaceuticals receives FDA Complete Response Letter for SPN-830, an investigational apomorphine infusion device for Parkinson's disease. CRL indicates additional review needed for product quality and infusion device master file. No clinical safety or efficacy issues identified.

SUPN

Read More
2 minute read

Palatin Technologies Eyes Growing $6B Dry Eye Disease Market With Late-Stage Study Data

By Vandana Singh
April 8, 10:02 AM
Palatin Technologies unveils Phase 3 PL9643 MELODY-1 trial results for dry eye disease treatment, showcasing statistically significant efficacy in pain reduction and secondary symptoms. PL9643 demonstrates superior safety and tolerability compared to existing treatments, promising a differentiated solution in the $6.11 billion dry eye disease market.

PTN